Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: August 30, 2022 Report Code: GDGMDHC22300IDB-ST

Select Item

COPD Pipeline Drugs Market Overview

Chronic Obstructive Pulmonary Disease (COPD) symptoms include inability to completely breathe out air from the lungs leading to shortness of breath. Other symptoms include cough, fatigue, and chest pain.

The COPD pipeline drugs market research report provides an analysis of the COPD drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for COPD and features dormant and discontinued projects.

COPD Pipeline Drugs Market Segmentation by Targets

Some of the key targets of the COPD pipeline drugs market are Beta 2 Adrenergic Receptor, Phosphodiesterase 4, Muscarinic Acetylcholine Receptor M3, Glucocorticoid Receptor, Interleukin 33, Cholinergic Receptor Muscarinic, Nuclear Factor Erythroid 2 Related Factor 2, Thymic Stromal Lymphopoietin, Alpha 1 Antitrypsin, and Arachidonate 5 Lipoxygenase among others.

COPD Pipeline Drugs Market Analysis, by Key Targets

COPD Pipeline Drugs Market Analysis, by Key Targets

To know more about the targets in the COPD pipeline drugs market, , download a free report sample

COPD Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the COPD pipeline drugs market are Beta 2 Adrenergic Receptor Agonist, Phosphodiesterase 4 Inhibitor, Muscarinic Acetylcholine Receptor M3 Antagonist, Glucocorticoid Receptor Agonist, Interleukin 33 Inhibitor, Cholinergic Receptor Muscarinic Antagonist, Thymic Stromal Lymphopoietin Inhibitor, Alpha 1 Antitrypsin Replacement, and Arachidonate 5 Lipoxygenase Inhibitor among others.

COPD Pipeline Drugs Market Analysis, by Key Mechanisms of Action

COPD Pipeline Drugs Market Analysis, by Key Mechanisms of Action

To know more about MoA in the COPD pipeline drugs market, , download a free report sample

COPD Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the COPD pipeline drugs market are inhalational, oral, intravenous, subcutaneous, nasal, parenteral, topical, intraarticular, transdermal, and intramuscular among others.

COPD Pipeline Drugs Market Analysis, by Routes of Administration

COPD Pipeline Drugs Market Analysis, by Routes of Administration

To know more about RoA in the COPD pipeline drugs market, download a free report sample

COPD Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the COPD pipeline drugs market are Small Molecule, Monoclonal Antibody, Biologic, Cell Therapy, Recombinant Protein, Antisense Oligonucleotide, Synthetic Peptide, Blood Derivative, and Gene-Modified Cell Therapy among others.

COPD Pipeline Drugs Market Analysis, by Molecule Types

COPD Pipeline Drugs Market Analysis, by Molecule Types

For more insights on molecule type, download a free report sample

COPD Pipeline Drugs Market Segmentation by Companies

Some of the leading companies in the COPD pipeline drugs market are AstraZeneca Plc, GSK plc, MD Healthcare Inc, Chiesi Farmaceutici SpA, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, Mariposa Health Ltd, Respiratorius AB, Crystec Ltd, Foresee Pharmaceuticals Co Ltd, iCeutica Inc, Korea United Pharm Inc, LTT Bio-Pharma Co Ltd, Aquilon Pharmaceuticals SA, and Boehringer Ingelheim International GmbH among others.

COPD Pipeline Drugs Market Analysis, by Leading Companies

COPD Pipeline Drugs Market Analysis, by Leading Companies

To know more about the leading companies in the COPD pipeline drugs market, download a free report sample

COPD Pipeline Drugs Market Report Overview

Key Targets Beta 2 Adrenergic Receptor, Phosphodiesterase 4, Muscarinic Acetylcholine Receptor M3, Glucocorticoid Receptor, Interleukin 33, Cholinergic Receptor Muscarinic, Nuclear Factor Erythroid 2 Related Factor 2, Thymic Stromal Lymphopoietin, Alpha 1 Antitrypsin, and Arachidonate 5 Lipoxygenase
Key Mechanisms of Action Beta 2 Adrenergic Receptor Agonist, Phosphodiesterase 4 Inhibitor, Muscarinic Acetylcholine Receptor M3 Antagonist, Glucocorticoid Receptor Agonist, Interleukin 33 Inhibitor, Cholinergic Receptor Muscarinic Antagonist, Thymic Stromal Lymphopoietin Inhibitor, Alpha 1 Antitrypsin Replacement, and Arachidonate 5 Lipoxygenase Inhibitor
Key Routes of Administration Inhalational, Oral, Intravenous, Subcutaneous, Nasal, Parenteral, Topical, Intraarticular, Transdermal, and Intramuscular
Key Molecule Types Small Molecule, Monoclonal Antibody, Biologic, Cell Therapy, Recombinant Protein, Antisense Oligonucleotide, Synthetic Peptide, Blood Derivative, and Gene-Modified Cell Therapy
Key Companies AstraZeneca Plc, GSK plc, MD Healthcare Inc, Chiesi Farmaceutici SpA, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, Mariposa Health Ltd, Respiratorius AB, Crystec Ltd, Foresee Pharmaceuticals Co Ltd, iCeutica Inc, Korea United Pharm Inc, LTT Bio-Pharma Co Ltd, Aquilon Pharmaceuticals SA, and Boehringer Ingelheim International GmbH

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AB Science SA
AB2 Bio Ltd
Acahealth Pharma and Biotech Co Ltd
Aeon Respire Inc
Afimmune Biopharma Ltd
AIBIOS Co Ltd
Akari Therapeutics Plc
AlgiPharma AS
Allinaire Therapeutics LLC
Alveolus Bio Inc
Amgen Inc
Angiocrine Bioscience Inc
Apollo Therapeutics LLC
Aquilon Pharmaceuticals SA
Aridis Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Atriva Therapeutics GmbH
AusBio Ltd
Axolo Pharma Inc
Bai Shuo Beijing Pharmaceutical Technology Co Ltd
Bayer AG
BioMarck Pharmaceuticals Ltd
Biotoxtech Co Ltd
Boehringer Ingelheim International GmbH
C4X Discovery Holdings Plc
CALYXHA Biotechnologies GmbH
Cambryn Biologics LLC
Cantex Pharmaceuticals Inc
Cellular Biomedicine Group Inc
Celon Pharma SA
Chiesi Farmaceutici SpA
Cipla Ltd
Circassia Group Plc
Clarametyx Biosciences Inc
Covenant Therapeutics LLC
Crystec Ltd
CSL Ltd
Cureveda LLC
Curovir AB
Cytokinetics Inc
Denovo Biopharma LLC
Diadem Biotherapeutics Inc
Diffusion Pharmaceuticals Inc
Dimerix Ltd
Domainex Ltd
Eisai Co Ltd
EmphyCorp Inc
Enalare Therapeutics Inc
Enzychem Lifesciences Corp
EpiEndo Pharmaceuticals Ehf
Epitracker Inc
ethris GmbH
Evaxion Biotech ApS
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Galephar Pharmaceutical Research Inc
Gilead Sciences Inc
Glenmark Pharmaceuticals Ltd
Grifols SA
GSK plc
Gurus BioPharm Inc
Hangzhou Metai Pharmaceutical Technology Co Ltd
Haplnscience Inc
iCeutica Inc
Icure Pharmaceutical Inc
Incannex Healthcare Ltd
Inmagene Biopharmaceuticals Ltd
InMed Pharmaceuticals Inc
Inmunotek SL
Insmed Inc
InStatin Inc
INVENT Pharmaceuticals Inc
Invion Ltd
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Joincare Pharmaceutical Group Industry Co Ltd
KBP Biosciences Co Ltd
KeyMed Biosciences Inc
Kinaset Therapeutics Inc
Kither Biotech Srl
Korea United Pharm Inc
Koutif Therapeutics LLC
Kyowa Kirin Co Ltd
Landos Biopharma Inc
Laurel Therapeutics
LTT Bio-Pharma Co Ltd
Mabwell Shanghai Bioscience Co Ltd
Mariposa Health Ltd
MD Healthcare Inc
MDimune Inc
Mereo Biopharma Group Plc
Meridigen Biotech Co Ltd
Metagone Biotech Inc
MIFCOR Inc
Modulus Discovery Inc
Naegis Pharmaceuticals Inc
NB Health Laboratory Co Ltd
NeuImmune Inc
Novabiotics Ltd
NovaCell Technology Inc
Novartis AG
Nuvara Therapeutics LLC
Omnispirant Ltd
Orchid Pharma Ltd
Organicell Regenerative Medicine Inc
Orphomed Inc
Palo BioFarma SL
Pantherics Inc
PharmaLundensis AB
Pharmaxis Ltd
Prous Institute for Biomedical Research SA
Pulmatrix Inc
Pulmotect Inc
Qu Biologics Inc
RAGE Biotech Pty Ltd
Regeneron Pharmaceuticals Inc
Renovion Inc
Resolys Bio Inc
Respiratorius AB
Rhizen Pharmaceuticals SA
RS BioTherapeutics Inc
Rubedo Life Sciences Inc
S.Biomedics Co Ltd
San Rocco Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Serenity Bioworks Inc
Shanghai KE Pharmaceutical Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Silurian Pharmaceuticals Inc
Silver Valley Pharmaceutical Co Ltd
SMSbiotech Inc
SolAeroMed Inc
SpliSense Ltd
sterna biologicals Gmbh & Co KG
Sulfateq BV
Surrozen Inc
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Regend Therapeutics Co Ltd
Symmune Therapeutics LLC
Synovo GmbH
Syntrix Pharmaceuticals
Taiho Pharmaceutical Co Ltd
Tetherex Pharmaceuticals Corp
TFF Pharmaceuticals Inc
Therapeutic Solutions International Inc
Theratrophix LLC
Theravance Biopharma Inc
Thirty Respiratory Ltd
Torrent Pharmaceuticals Ltd
Unity Biotechnology Inc
Validus Cellular Therapeutics Inc
Verona Pharma Plc
Verra Therapeutics LLC
Vicenna Pharmaceuticals Inc
Vitti Labs LLC
vTv Therapeutics Inc
Zhengda Tianqing Pharmaceutical Group Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Obstructive Pulmonary Disease (COPD) – Overview

Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Obstructive Pulmonary Disease (COPD) – Companies Involved in Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) – Drug Profiles

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products

Chronic Obstructive Pulmonary Disease (COPD) – Product Development Milestones

Featured News & Press Releases

Aug 09, 2022: Dimerix announces new patent family application for DMX-700

Aug 09, 2022: Verona Pharma to announce top-line data from Phase 3 ENHANCE-2 Trial of nebulized ensifentrine for COPD

Aug 09, 2022: Verona Pharma announces ensifentrine meets primary endpoint in phase 3 ENHANCE-2 trial for COPD

Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound

Jul 04, 2022: DMX-700 shows significant efficacy with 80% reduction in lung injury of COPD

Jun 09, 2022: Verona Pharma completes enrollment in phase 3 ENHANCE-1 trial evaluating ensifentrine for maintenance treatment of COPD

Jun 06, 2022: Verona Pharma to host KOL event on June 16, 2022

May 23, 2022: Therapeutic Solutions International receives IND number 28508 for Chronic Obstructive Pulmonary Disease clinical trial and enters binding discussions with FDA for initiation of phase I/II Clinical Trial

May 18, 2022: Successful completion of phase I study for lead asset EP395

May 18, 2022: Verona Pharma to present successful TQT analysis demonstrating no clinically relevant effect on cardiac conduction at the American Thoracic Society 2022

May 12, 2022: Phase III lung Adult Stem Cell company announces and files patent on leukine-induced myeloid derived suppressor cells and JadiCell for treatment of COPD

May 09, 2022: Therapeutic Solutions International files Investigational New Drug application for treatment of Chronic Obstructive Pulmonary Disease (COPD) using JadiCell universal donor adult stem cells

Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine

Mar 28, 2022: Sanofi continues on path to industry leadership in Immunology with Dupixent (dupilumab) as key driver

Mar 21, 2022: Pulmatrix announces positive top-line data evaluating PUR1800 in Patients with Stable COPD

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, 2022

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Respiratory reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more